Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
On November 6, 2026, Davion Healthcare Plc (the “Company”
or “Davion”) issued a press release announcing that it had entered into a non-exclusive financial advisory agreement with
Vienna Capital Partners LLC to support its proposed acquisition financing strategy for 2027.
The Company has established an initial aggregate financing objective
of US$100 million, with the potential to increase this as its acquisition programme develops. The Company intends to focus principally
on senior secured, non-convertible debt financing from institutional lenders, private credit providers and other financial institutions
to support acquisitions of established, profitable and cash-generative businesses, principally in the United States.
The US$100 million financing objective is an indicative aggregate target
and does not represent an established, committed or currently available credit facility. No binding lender commitments have been secured
under the proposed programme. Any future financing will be subject to lender approval, satisfactory due diligence, definitive documentation
and applicable conditions. There can be no assurance that financing will be obtained in any particular amount or on acceptable terms,
or that any proposed acquisition will be completed.
A copy of the press release dated November 6, 2026 is furnished as
Exhibit 99.1 to this Report on Form 6-K.
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
For release 6 November 2026
DAVION HEALTHCARE
PLC APPOINTS VIENNA CAPITAL PARTNERS TO SUPPORT US$100 MILLION ACQUISITION FINANCING STRATEGY
Financial advisory appointment to support planned
acquisitions of profitable, revenue-generating businesses during 2027
Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Company”),
a developer of non-invasive health monitoring technologies, announces that it has entered into a non-exclusive financial advisory agreement
with Vienna Capital Partners LLC (“Vienna Capital”), a New York-based financial services firm, to support its proposed US$100
million-plus acquisition financing strategy for 2027.
The appointment forms part of Davion’s strategy to build a diversified
healthcare and related services group through the acquisition of established, profitable and cash-generative businesses, principally in
the United States. It follows the Company’s recent announcement of its proposed $13.5 million acquisition of Healthcare Stat Homecare
Inc., a profitable US home healthcare business.
Under the agreement, Vienna Capital will advise Davion on institutional
financing structures and potential funding arrangements to support its acquisition programme. The Company intends to focus principally
on senior secured, non-convertible debt financing from institutional lenders, private credit providers and other financial institutions,
with the objective of supporting acquisitions while minimising equity dilution for existing shareholders.
Davion has established an initial aggregate financing objective of
US$100 million, with the potential to increase this as its acquisition programme develops.
The proposed financing is intended to support multiple acquisitions
rather than a single transaction, with opportunities assessed according to their profitability, cash generation, asset backing and strategic
contribution to the Group.
The Company will focus on established businesses with proven operating
histories, sustainable revenues and positive cash flow. Financing arrangements are expected to be evaluated on a transaction-by-transaction
basis and may be undertaken through Davion’s US subsidiary, Davion Healthcare Corp, or designated acquisition vehicles.
Glenn Williams, Chief Executive Officer of Davion, commented:
“Our strategy is to build a substantial healthcare and related
services group by combining our proprietary technologies with established, profitable businesses that bring revenues, earnings and operational
capabilities. The appointment of Vienna Capital is an important step in developing the financing arrangements to support that ambition.
Our initial US$100 million financing objective reflects the scale of the acquisition opportunities we intend to pursue during 2027, and
our preference is to use institutional debt wherever commercially appropriate, allowing us to expand while limiting dilution for existing
shareholders. We look forward to working with Vienna Capital as we progress our acquisition programme.”
Dr Vincent deFilippo, Chief Executive Officer of Vienna Capital
Partners LLC, added:
“Davion has an exciting opportunity to combine innovative
healthcare technologies with established, profitable businesses to build a diversified healthcare group. We believe its acquisition strategy
offers a compelling platform for long-term growth, and we are pleased to support the Company in evaluating institutional financing opportunities
and developing the financial structures needed to pursue its ambitions.”
Financing Arrangements
Vienna Capital will work with Davion to evaluate potential financing
structures, institutional lending markets and funding alternatives appropriate to individual acquisitions.
The Company anticipates that financing arrangements, if successfully
negotiated, will be tailored to individual transactions and may be implemented progressively throughout 2027.
Davion’s initial US$100 million financing objective is an indicative
aggregate target and does not represent an established, committed or currently available credit facility. No binding lender commitments
have been secured under the proposed programme.
Any future financing will be subject to lender approval, satisfactory
due diligence, definitive documentation and applicable conditions. There can be no assurance that financing will be obtained in any particular
amount or on acceptable terms, or that any proposed acquisition will be completed.
The Company will provide further updates as appropriate.
-ends-
Media Enquiries
Rosewood Communications
+44 (0) 20 7653 8702
davion@rosewoodpr.co.uk
Investor Relations Inquiries
Mark Komonoski
Partner
Integrous Communications
Toll Free: 877-255-8483
Mobile: 403-470-8384
mkomonoski@integcom.us
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company
developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies
outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is an FDA-registered
at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s
broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood
pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development and commercialisation
of its proprietary technologies with complementary acquisitions intended to expand the Group’s revenues, earnings, operating capabilities
and presence in healthcare and related services markets.
Further information is available at www.davionhealthcare.com.
About Vienna Capital Partners LLC
Vienna Capital Partners LLC is a New York-based, FINRA-registered financial
services firm and family office specialising in strategic capital solutions, investment banking advisory and management consulting services
for private and publicly traded companies.
The firm advises on financing structures, mergers and acquisitions
and corporate growth strategies, with activities spanning sectors including healthcare, energy, consumer products, private credit, logistics
and technology infrastructure.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning
of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.
The statements in this release are based upon the current beliefs and
expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from
those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such differences, including,
but not limited to, the availability and terms of acquisition financing, the Company’s ability to identify, negotiate and complete
suitable acquisitions, the financial performance of acquired businesses, the integration of acquired operations, the results of product
evaluations, studies, regulatory reviews and commercial adoption, the challenges inherent in new product development initiatives, the
impact of competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional
capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, and other risks
discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking
statements, or any information contained in this press release or in other public disclosures, except as required by applicable law.
The investing public is reminded that only announcements or information
about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
